Citi analyst Samantha Semenkow initiates coverage on $BioAge Labs (BIOA.US)$ with a buy rating, and sets the target price at $45.
According to TipRanks data, the analyst has a success rate of 38.8% and a total average return of -8.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $BioAge Labs (BIOA.US)$'s main analysts recently are as follows:
BioAge Labs, a clinical-stage biotech centered on developing treatments for metabolic diseases, is advancing its lead asset, azelaprag, an oral small molecule that stimulates the apelin receptor and is currently in development for obesity. The company's shares are considered to have a favorable risk/reward profile leading up to the STRIDES readout. The product's oral formulation and ease of manufacturing, coupled with strong preclinical data, suggest it could have a promising clinical profile for treating obesity.
Initial findings indicate that BioAge Labs' azelaprag shows promise, potentially enhancing weight loss when used alongside GLP-1s, and also contributing to better body composition and higher quality of weight loss. Early data suggest that azelaprag not only facilitates weight reduction but also has a positive effect on muscle.
BioAge Labs, a clinical stage biotechnology firm concentrating on metabolic diseases, is recognized for its lead drug Azelaprag, which stands out due to its unique mechanism that mimics exercise, targeting obesity.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
